Stage
No active trials
Next date
None yet
Trials
0 active
6 in total · 1 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection”In the company’s words, NCT05204563 on ClinicalTrials.gov
- Tested for
- Bacterial Infections (4 trials), Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia, Complicated Urinary Tract Infection Including Acute Pyelonephritis
- Main trialPhase 3
- “This study aims to compare treatment with Imipenem/Cilastatin-XNW4107 (IMI-XNW4107) with imipenem/cilastatin/relebactam (IMI/REL) in participants with hospital-acquired or ventilator-associated bacterial pneumonia (HABP or VAPB, respectively). The primary hypothesis is that IMI-XNW4107 is non-inferior to IMI/REL in all-cause mortality.”In the company’s words, NCT05204563 on ClinicalTrials.gov
Other drugs for Bacterial Infections
- DTpaGSK · Phase 3
- 13-Valent Pneumococcal Polysaccharide Conjugate VaccineCanSino Biologics Inc. · Phase 3
- Group ACYW135 Meningococcal Conjugate VaccineSinovac Biotech Co., Ltd · Phase 3
- 20vPCVSanofi · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- VLA15Pfizer · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Completed | 29 Sep 2024 | Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2) | |
| Phase 3Unknown | Jun 2025 | Evaluation of the Efficacy and Safety of Intravenous Imipenem/Cilastatin/XNW4107 in Comparison With Meropenem in Hospitalized Adults With cUTI Including AP (EudraCT no. 2022-000061-40) | |
| Phase 1Completed | 28 Feb 2021 | Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin | |
| Phase 1Completed | 15 May 2021 | Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects | |
| Phase 1Completed | 30 Oct 2021 | Pharmacokinetics of XNW4107 in Subjects With Various Degrees of Renal Function | |
| Phase 1Completed | 30 Oct 2021 | To Evaluate the Pharmacokinetics of XNW4107 in Healthy Adult Young Females and in Healthy Adult Elderly Males and Females. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026